Treatment Pathways
Cross-source consensus on Treatment Pathways from 1 sources and 5 claims.
1 sources · 5 claims
Dosage & preparation
Highlighted claims
- People with osteopenia were modelled as receiving colecalciferol and calcium. — Cost-effectiveness of osteoporotic fracture risk assessment in people with intellectual disabilities: a UK NHS modelling study
- People with normal bone mineral density were modelled as receiving no treatment. — Cost-effectiveness of osteoporotic fracture risk assessment in people with intellectual disabilities: a UK NHS modelling study
- A 10-year major osteoporotic fracture risk of at least 10% was defined as a positive risk assessment. — Cost-effectiveness of osteoporotic fracture risk assessment in people with intellectual disabilities: a UK NHS modelling study
- A 10-year hip fracture risk of at least 3% was defined as a positive risk assessment. — Cost-effectiveness of osteoporotic fracture risk assessment in people with intellectual disabilities: a UK NHS modelling study
- People diagnosed with osteoporosis were modelled as receiving alendronate plus colecalciferol and calcium. — Cost-effectiveness of osteoporotic fracture risk assessment in people with intellectual disabilities: a UK NHS modelling study